257892-31-2 Usage
Uses
Used in Pharmaceutical Industry:
N-DESMETHYL ROSIGLITAZONE is used as a therapeutic agent for the treatment of type 2 diabetes. As a metabolite of rosiglitazone, it plays a role in managing blood sugar levels and improving insulin sensitivity in patients with this condition.
Used in Research and Development:
N-DESMETHYL ROSIGLITAZONE is used as a research compound for studying the mechanisms of type 2 diabetes and the role of PPARγ ligands in its treatment. This helps in the development of new drugs and therapies for diabetes management.
Used in Drug Metabolism Studies:
N-DESMETHYL ROSIGLITAZONE is used as a model compound in drug metabolism studies, particularly focusing on the role of the cytochrome P450 (CYP) isoform CYP2C8 in the metabolism of rosiglitazone. This aids in understanding the metabolic pathways and potential drug interactions involving this enzyme.
Used in Quality Control and Standardization:
N-DESMETHYL ROSIGLITAZONE is used as a reference material for quality control and standardization in the pharmaceutical industry. It helps ensure the consistency, purity, and potency of rosiglitazone-containing medications.
Check Digit Verification of cas no
The CAS Registry Mumber 257892-31-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,7,8,9 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 257892-31:
(8*2)+(7*5)+(6*7)+(5*8)+(4*9)+(3*2)+(2*3)+(1*1)=182
182 % 10 = 2
So 257892-31-2 is a valid CAS Registry Number.
InChI:InChI=1/C17H17N3O3S/c21-16-14(24-17(22)20-16)11-12-4-6-13(7-5-12)23-10-9-19-15-3-1-2-8-18-15/h1-8,14H,9-11H2,(H,18,19)(H,20,21,22)
257892-31-2Relevant academic research and scientific papers
Kaspera, Ruediger,Naraharisetti, Suresh B.,Evangelista, Eric A.,Marciante, Kristin D.,Psaty, Bruce M.,Totah, Rheem A.
, p. 681 - 691 (2011)
Genetic polymorphisms in CYP2C8 can influence the metabolism of important therapeutic agents and cause interindividual variation in drug response and toxicity. The significance of the variant CYP2C8*3 has been controversial with reports of higher in vivo
